The Defocus Incorporated Multiple Segments (DIMS) clinical study included a two year randomized controlled trial, which then extended to investigate continued efficacy over six years of wear, plus groups who switched from single vision to DIMS and back again. There was no evidence of a rebound effect. Visual acuity and binocular visual functions were similar across groups.
There’s a lot we already know about Essilor Stellest spectacle lenses for correcting and controlling myopia. This article explores recent published studies on visual fields, a crossover trial and the 3-year and 4-year clinical trial data.
The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
Our Q&A format explores new technologies, products and research with experts. In this interview, Dr Sherman Tung, optometrist from Canada, shares his experience with The SightGlass Vision DOT 0.2 Lens in his practice, from prescribing to parent explanations and clinical outcomes.
Peripheral vision function and reading speed were unaffected by highly aspherical (HAL) and slightly aspherical lenslet (SAL) spectacle lens designs compared to single vision lenses. Low contrast acuity was slightly reduced through the lenslet zone.
In this case, a colleague has his first experience with the new Essilor Stellest spectacle lens for childhood myopia, with discussion including when to change the prescription and when to stop treatment.
This study evaluated the visual performance and optical quality of three lenslet design spectacle lenses. While all degraded visual performance in some capacity, the concentric design (highly and slightly aspherical) lenses generally had a significantly lower impact on both acuity and contrast than honeycomb configuration (HC).
Spectacle lenses which effectively control myopia progression are the next phase in widespread uptake of myopia management. Learn more about the Essilor Stellest lens, from myopia control to vision and visual function outcomes.
